Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
brimonidine tartrate, Quantity: 2 mg/mL
Abbvie Pty Ltd
Eye Drops, solution
Excipient Ingredients: polyvinyl alcohol; benzalkonium chloride; citric acid; hydrochloric acid; sodium citrate dihydrate; sodium chloride; sodium hydroxide; purified water
Ophthalmic
2.5mL (sample pack) shelf life is 24 months below 25 deg, 5mL. Shelf life is 30 months below 30 deg
(S4) Prescription Only Medicine
INDICATIONS:ENIDIN eye drops are effective as monotherapy for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension in whom (Beta symbol)-blockers are not tolerated or are contraindicated. INDICATIONS AS AT 7 DECEMBER 1999: ENIDIN eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension.ENIDIN eye drops can be used in the treatment of glaucoma either as monotherapy or in combination with topical beta-blockers.
Visual Identification: Clear, greenish-yellow solution.; Container Type: Bottle; Container Material: LDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2002-04-24
ENIDIN ® Eye Drops-CMI Version 2.0-PIv5.0 Page 1 of 4 ENIDIN ® EYE DROPS _ _ [brimonidine tartrate] CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ENIDIN ® eye drops, including how to use the eye drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using ENIDIN ® eye drops against the benefits they expect it will have for you. If you have any concerns about using/taking this medicine, ask your doctor or pharmacist. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT ENIDIN ® EYE DROPS ARE USED FOR ENIDIN ® eye drops are used to lower raised pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure. Glaucoma is usually caused by a build up of the fluid which flows through the eye. This build up occurs because the fluid drains out of your eye more slowly than it is being pumped in. Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight. Damage can progress so slowly that the person is not aware of this gradual loss of sight. Sometimes even normal eye pressure is associated with damage to the back of the eye. There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or optometrist. If glaucoma is not treated it can lead to serious problems, including total blindness. In fact, untreated glaucoma is one of the most common causes of blindness. Although ENIDIN ® eye drops help control your glaucoma, it does not cure it. For more information about glaucoma, contact the Glaucoma Australia Inc. (telephone 180 Read the complete document
ENIDIN ® Eye Drops PI v6-CCDS v2.1 1 AUSTRALIAN PRODUCT INFORMATION – ENIDIN ® (BRIMONIDINE TARTRATE) EYE DROPS 1 NAME OF THE MEDICINE Brimonidine tartrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of ENIDIN ® 0.2% Eye Drops contains 2.0 mg brimonidine tartrate (equivalent to 1.32 mg as brimonidine free base). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Eye drops, solution. ENIDIN ® 0.2% is a sterile ophthalmic solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ENIDIN ® eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. ENIDIN ® eye drops can be used in the treatment of glaucoma as either monotherapy or in combination with topical beta-blockers. 4.2 DOSE AND METHOD OF ADMINISTRATION MONOTHERAPY: The recommended dose is one drop of ENIDIN ® eye drops in the affected eye(s) twice daily, approximately 12 hours apart. COMBINATION THERAPY: The recommended dose is one drop of ENIDIN ® eye drops in the affected eye(s) twice daily, approximately 12 hours apart. In order to minimise systemic absorption of ENIDIN ® eye drops, apply pressure to the tear duct immediately following administration of the drug. As with all eye drops containing benzalkonium chloride as a preservative, there is potential for incompatibility with other topical ophthalmic medications. If more than one topical ophthalmic drug is to be used, other eye drops should not be used within five to ten minutes of using ENIDIN ® eye drops. ENIDIN ® Eye Drops PI v6-CCDS v2.1 2 4.3 CONTRAINDICATIONS ENIDIN ® eye drops are contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. This product is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. ENIDIN ® eye drops are also contraindicated in neonates and infants (children under the age of 2 years) 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE IDENTIFIED PRECAUTIONS Read the complete document